Combined androgen blockade with bicalutamide for advanced prostate cancer
Author:
Publisher
Wiley
Subject
Cancer Research,Oncology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.24395/fullpdf
Reference24 articles.
1. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy;Moul;J Urol,2004
2. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy;Freedland;JAMA,2005
3. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials;Prostate Cancer Trialists' Collaborative Group;Lancet,2000
4. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial;Schellhammer;Urology,1997
5. Tolerability of antiandrogens in the treatment of prostate cancer;Fourcade;UroOncology,2004
Cited by 164 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Risks associated with cognitive function and management strategies in the clinical use of ADT: a systematic review from clinical and preclinical studies;Supportive Care in Cancer;2024-07-31
2. PSA doubling time 4.65 months as an optimal cut-off of Japanese nonmetastatic castration-resistant prostate cancer;Scientific Reports;2024-07-03
3. UBX‐390: A Novel Androgen Receptor Degrader for Therapeutic Intervention in Prostate Cancer;Advanced Science;2024-07-03
4. Comparison of oncological outcomes of upfront androgen receptor signaling inhibitors and combined androgen blockade in Japanese patients with metastatic castration-sensitive prostate cancer;Global Health & Medicine;2024-06-30
5. Prognostic outcomes in Japanese patients with metastatic castration‐sensitive prostate cancer: Comparative assessments between conventional androgen deprivation therapy (ADT) and ADT with novel androgen receptor signal inhibitor;International Journal of Urology;2024-05-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3